Pipeline
Our pipeline is focused on half-life extended T cell engager drug opportunities across a broad range of solid tumors as well as autoimmune indications
Novel targets
Solid tumor program
Addressable patients*
Target and engager
Discovery > Lead optimisation > IND enabling
Status
TC25
NSCLC, GI, HNSCC, others
> 60,000
HLA-A2
TC25
αCD3 TCE
Novel Targets
Solid Tumors**
> 60,000
Multi-HLA
Undisclosed
TC11
Cutaneous & uveal melanoma
10,000
HLA-A2
TC11
αCD3 TCE
Solid tumor program
TC25
NSCLC, GI, HNSCC, others
Status
Addressable patients*
> 60,000
HLA-A2
Target and engager
TC25
αCD3 TCE
Solid tumor program
Novel Targets
Solid Tumors**
Status
Addressable patients*
> 60,000
Multi-HLA
Target and engager
Undisclosed
Solid tumor program
TC11
Cutaneous & uveal melanoma
Status
Addressable patients*
10,000
HLA-A2
Target and engager
TC11
αCD3 TCE
* Addressable patients, HLA positive & target positive, US only
** High potential indications for TCEs including MSS CRC, Gastric, Esophageal (Sq./Ad), Lung (Sq/Ad), HNSCC, Bladder, Pancreatic
Autoimmune program
Multi-indication
Autoimmune
TC301, Undisclosed
Autoimmune program
Multi-indication
Status
Annual addressable metastatic US patients
Autoimmune
Target and engager
TC301, Undisclosed